Trials / Completed
CompletedNCT02786901
LE Gel for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery
A Phase 3, Multi-Center, Double-Masked, Vehicle-Controlled, Randomized, Parallel-Group Study to Assess Loteprednol Etabonate Ophthalmic Gel, (BID and TID) Versus Vehicle Gel
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 600 (actual)
- Sponsor
- Bausch & Lomb Incorporated · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Loteprednol Etabonate Ophthalmic Gel, (BID and TID) versus Vehicle Group for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery.
Detailed description
A Phase 3, Multi-Center, Double-Masked, Vehicle Controlled, Randomized, Parallel-Group Study to Assess Loteprednol Etabonate Ophthalmic Gel, (BID and TID) versus Vehicle Group for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Loteprednol Etabonate Ophthalmic Gel dosed TID | Gel |
| DRUG | Loteprednol Etabonate Ophthalmic Gel dosed BID | Gel |
| DRUG | Vehicle Gel | Gel |
Timeline
- Start date
- 2016-06-01
- Primary completion
- 2017-06-13
- Completion
- 2017-07-01
- First posted
- 2016-06-01
- Last updated
- 2021-01-08
- Results posted
- 2020-04-14
Locations
6 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT02786901. Inclusion in this directory is not an endorsement.